and etf dehydrogenase n heptanoic acid supplemented compositions can be used in the treatment of the following fatty acid defects translocase deficiency carnitine palmitoyltransferase i and ii deficiencies l 3 hydroxyacyl coa dehydrogenase lchad deficiency very long chain acyl coa dehydrogenase vlcad deficiency and short chain acyl coa dehydrogenase scad deficiency treatment of the infant with severe neonatal translocase deficiency identified in example 1 using triheptanoin supplemented low fat formula was successful additionally there is support for the correlation between the clinical response to triheptanoin therapy and the in vitro mass spectrometry analysis of the infant 39 s amniocytes at 38 weeks gestation delivery of the infant whose amniocytes tested positive for severe translocase deficiency as described in example 1 was accomplished cord blood was analyzed for total and free carnitine levels as well as levels of individual acylcarnitines by tandem mass spectrometry yang et al 1998 u201c identification of four novel mutations in patients with carnitine palmitoyltransferase ii cpt ii deficiency u201d mol genet metab 64 229 236 maternal blood at the time of delivery was also assayed for these same levels results confirmed that the infant suffered from severe translocase deficiency within the first twelve hours after delivery a low fat formula supplemented with triheptanoin was fed to the infant via a nasogastric tube subsequent feedings with the triheptanoin supplemented formula were given at the same frequency as any full term infant supplements of carnitine biotin.